Physician

Kavitha Paramanathan, M.D

According to 2025 Medicare claims, Kavitha Paramanathan, M.D (NPI: 1700021847) practices hematology/oncology in the Columbia, SC market, with the plurality of this provider's patient population coming from Lexington, SC. This provider's primary affiliated billing organization is LEXINGTON HEALTH INC (NPI: 1932706264; TIN: 85-2276567) and primary practice location at 29169-4848.

Paramanathan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 833 traditional Medicare patients, billed 175,966 HCPCS/CPT codes, and received $2,950,009 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,152 prescription claims across 165 beneficiaries totaling $1,068,798 in drug costs, led by Abiraterone Acetate (Abiraterone Acetate). DME data shows 65 claims. Open Payments data shows 36 records totaling $704. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $51,751 to $2,950,009. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $123,732 and ending at $1,068,798. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	160	923	$51,751
2016	196	1,120	$49,663
2017	296	2,210	$116,782
2018	349	1,884	$132,303
2019	351	2,232	$92,631
2020	319	1,404	$99,309
2021	324	1,273	$108,270
2022	354	930	$64,814
2023	240	4,680	$110,275
2024	833	175,966	$2,950,009

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	55	494	$123,732
2016	70	554	$357,276
2017	134	1,226	$666,764
2018	164	1,558	$1,070,102
2019	146	1,382	$1,635,641
2020	148	1,282	$2,325,386
2021	166	1,550	$2,590,753
2022	230	1,363	$2,279,643
2023	143	1,024	$211,963
2024	165	1,152	$1,068,798

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	24	$464
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	55	$6,448
2022	N/R	23	$164
2023	N/R	12	$3,102
2024	N/R	65	$1,858

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	208	399	$93
80053	Blood test, comprehensive group of blood chemicals	197	607	$10
36415	Insertion of needle into vein for collection of blood sample	306	929	$8
80048	Blood test, basic group of blood chemicals (calcium, total)	196	448	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	343	1,096	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Abiraterone Acetate	Abiraterone Acetate	82	2,460	$223,108
Nerlynx	Neratinib Maleate	12	356	$204,821
Xtandi	Enzalutamide	13	390	$179,725
Eliquis	Apixaban	37	1,279	$25,228
Exemestane	Exemestane	41	2,610	$5,319

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	17	$858
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	12	$430
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	17	$320
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	19	$251

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	36	$704	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Kavitha Paramanathan, M.D?

Tedicare shows public-source Medicare data for Kavitha Paramanathan, M.D (NPI 1700021847), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Kavitha Paramanathan, M.D have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Kavitha Paramanathan, M.D?

Kavitha Paramanathan, M.D is linked to LEXINGTON HEALTH INC (billing NPI 1932706264) in the available physician profile data.

Does Kavitha Paramanathan, M.D have Open Payments data?

Kavitha Paramanathan, M.D has 36 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.